Back to Journals » Stem Cells and Cloning: Advances and Applications » Volume 3

Progress in stem cell-derived technologies for hepatocellular carcinoma

Authors Aravalli R 

Published 3 May 2010 Volume 2010:3 Pages 81—92

DOI https://doi.org/10.2147/SCCAA.S6886

Review by Single anonymous peer review

Peer reviewer comments 3



Rajagopal N Aravalli

Department of Radiology, University of Minnesota Medical School, Minneapolis, MN, USA

Abstract: Primary hepatocellular carcinoma (HCC) is a common malignancy that has a poor prognosis because it is often diagnosed at an advanced stage. HCC normally develops as a consequence of underlying liver disease and is most often associated with cirrhosis. Surgical resection and liver transplantation are the current best options to treat liver cancer. However, problems associated with liver transplantation, such as shortage of donors, risk of immune rejection, and tissue damage following surgery provided the impetus for development of alternative therapies. The emerging field of stem cell therapy has raised hopes for finding curative options for liver cancer. Stem cells have the ability not only to proliferate after transplantation but also to differentiate into most mammalian cell types in vivo. In this review, progress on stem cell-derived technologies for the treatment of liver cancer is discussed.

Keywords: liver, cancer, stem cell, therapy, hepatocellular carcinoma

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.